Tuominen RK, Tuomisto L, M\l=a"\nnist\l=o"\PT. Effect of modified brain histamine contents on prolactin and thyrotropin secretion in male rats. Eur J Endocrinol 1996;134:209-14. ISSN Effects of modified brain histamine contents on thyrotropin and prolactin secretion were studied in male rats. Under basal conditions the histamine content in the hypothalamus was approximately 8-10-fold higher than that in the striatum and the rest of the brain. L-Histidine (1000mg/kg, ip), a histamine precursor, and metoprine (20 mg/kg, ip), an inhibitor of histamine methyltransferase, elevated histamine content in the brain by 65% and 167%, respectively. When the treatments were given together an additive effect (119-250% increase) on brain histamine was observed. Metoprine significantly decreased serum prolactin levels, while L-histidine had no effect. This effect of metoprine was not modified by treatment with L-histidine. Thus, metoprine has an inhibitory effect on prolactin secretion that is not related to elevated brain histamine contents. The increased brain histamine content after L-histidine treatment had no effect on prolactin secretion. Basal levels of serum thyrotropin were decreased by both L-histidine and metoprine, L-histidine being more potent. In rats treated with \g=a\-fluoromethylhistidine, an inhibitor of L-histidine decarboxylase, the cold-induced (rats kept for 60 min at +4\s=deg\C)thyrotropin secretion was increased while the stress-induced prolactin secretion was decreased. In these rats, metoprine did not affect thyrotropin release but blunted the prolactin response. In conclusion, endogenous histamine (Fig. ) but significantly lowered serum TSH levels (Fig IB) in male rats. Metoprine (20 mg/kg, ip) significantly decreased both prolactin and TSH levels in serum (Fig. , B) . Neither the inhibitory effect of metoprine on prolactin levels nor the inhibitory effect of L-histidine on TSH levels was modified when L-histidine was administered to metoprine-pretreated rats (Fig. , B) .
Histamine modifies the release of anterior pituitary (AP) hormones in rats (1) . The site of action of histamine is generally not in the AP gland but in the hypothalamus, where histamine can modulate the function of other neurotransmitter systems or neurosecretory cells (2, 3) .
In the hypothalamus, most of which is inside the blood brain barrier (BBB), histamine is stored in nerves and can be released upon nerve stimulation (for a review, see Ref. 3). Histamine does not cross the BBB, and therefore its central effects on AP hormone release have been studied using microinfusions of the amine directly into the brain tissue or into the brain ventricles (1) .
Histamine, given peripherally by intra-arterial infu¬ sion (4) or centrally either by injection to the brain ventricles (5) or into the rostral hypothalamus (6) , increases prolactin secretion in male rats. Elevated basal prolactin levels in serum have also been measured in rats with portocaval anastomosis (7) . These rats have a very high level of endogenous histamine in the brain (8, 9) . Histamine has not been found to modify the release of prolactin from AP in vitro (10) . Histamine injected intracerebroventricularly or into anterior hypothalamus (11) inhibits cold-induced (rats kept for 30min at +4°C) thyrotropin (TSH) secretion in maie rats. Histamine does not modify the release of TSH from superfused AP cells (12) , indicating a central site of action for histamine.
In nervous tissue, histamine is synthesized from L-histidine by histidine decarboxylase (HDC) (EC 4.1.1.22) and degraded by histamine N-methyltransferase (HMT) (EC 2.1.1.8) (13) . L-Histidine, given intraperitoneally (ip), can be used to elevate brain histamine levels (14) , because L-histidine easily crosses the BBB and is decarboxylated in the brain to histamine by HDC. Metoprine, an HMT inhibitor (15) , has been used to increase brain histamine contents as well. Brain histamine can be depleted by using a-fluoromethylhistidine (a-FMH), which is a suicide substrate and a specific kcat-inhibitor of HDC (16) .
a-Fluoromethylhistidine inhibits stress-induced pro¬ lactin surges (17, 18) and morphine-induced prolactin secretion (19) , but has no effect on basal prolactin secretion (18, 20) in conscious male rats. Large doses of L-histidine given ip (21, 22) (Fig. ) but significantly lowered serum TSH levels (Fig IB) in male rats. Metoprine (20 mg/kg, ip) significantly decreased both prolactin and TSH levels in serum (Fig. , B) . Neither the inhibitory effect of metoprine on prolactin levels nor the inhibitory effect of L-histidine on TSH levels was modified when L-histidine was administered to metoprine-pretreated rats (Fig. , B) .
Effect of a-EMH and metoprine on serum TSH and prolactin levels after cold stress After a-FMH (100mg/kg + 50mg/kg, ip) there is a tendency to increase cold-induced (rats kept for 60 min at +4°C) TSH secretion although this is not significant (p = 0.08) (Fig. 2) . Metoprine (20mg/kg, ip) had no effect. After the 60-min cold exposure, serum prolactin levels were high (Fig. 2) . a-Fluoromethylhistidine and especially metoprine dramatically decreased the stressinduced prolactin secretion (Fig. 2 ). 3A ).
During a 60-min incubation period, the AP cells released 15% of their prolactin contents into the incubation medium (Fig. 3B) . Thyrotropin-releasing hormone (0.2µ 1/1, 10 min) increased prolactin release, but this effect was not significant. However, TRH increased significantly the prolactin release in metoprine (1 µ \/\)-ß cells (Fig. 3B) (34) . Therefore, the effect of metoprine on prolactin secretion might be due to, or mediated by, reduced vasopressin activity.
In the cold-stressed rats, serum prolactin levels were high. Histamine is one of the mediators of stress-induced prolactin secretion (2, (35) (36) (37) . fn rats treated with a-FMH, which depletes brain histamine, the cold-stressinduced prolactin secretion was significantly inhibited, which may indicate a role for endogenous histamine in this phenomenon. -Fluoromethylhistidine also inhib¬ ited restraint stress-induced prolactin secretion (17, 18) but did not affect basal prolactin levels (18 (12) .
Taken together, the present results indicate that: (i) treatment of rats with either L-histidine or metoprine increases brain histamine contents;
(ii) L-histidine does not affect basal levels of serum prolactin; (iii) metoprine decreases both basal and cold-stressstimulated prolactin release but these effects are not related to increased endogenous histamine levels;
(iv) in L-histidine-treated rats, basal TSH secretion is reduced;
(v) endogenous histamine has an inhibitory effect on TSH secretion, but may have both stimulatory and inhibitory regulation on prolactin release; (vi) metoprine is not a suitable drug for increasing endogenous histamine contents in hormonal studies.
